Company profile for Genmab

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arz...
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Denmark
Address
Address
Kalvebod Brygge 43 1560 Copenhagen V
Telephone
Telephone
+45 7020 2728
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-12-12/genmab-announces-completion-of-tender-offer-for-outstanding-common-shares-of-merus-nv-and-commence

PHARMIWEB
12 Dec 2025

https://www.globenewswire.com/news-release/2025/12/11/3203632/0/en/Genmab-to-Hold-2025-R-D-Update-and-ASH-Data-Review-Meeting.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197477/0/en/Transactions-With-Shares-and-Linked-Securities-in-Genmab-A-S-Made-by-Managerial-Employees-and-Their-Closely-Associated-Persons.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193366/0/en/Genmab-to-Participate-in-a-Fireside-Chat-at-the-Citi-Global-Healthcare-Conference-in-Miami.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/20/3192342/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Employees-in-Genmab.html

GLOBENEWSWIRE
20 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-20/transactions-with-shares-and-linked-securities-in-genmab-as-made-by-managerial-employees-and-their-closely-associated-persons

PHARMIWEB
20 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact Genmab and get a quotation

Genmab is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of HUMAN MONOCLONAL ANTIBODY TO CD4 (ZANOLIMUNAB) bulk offered by Genmab

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty